PI
CSTL icon

Putnam Investments’s Castle Biosciences CSTL Stock Holding History

Putnam Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$540K Sell
25,006
-789
-3% -$13.9K ﹤0.01% 922
2023
Q3 		$436K Buy
25,795
+10,283
+66% +$180K ﹤0.01% 942
2023
Q2 		$213K Buy
15,512
+1,056
+7% +$21.4K ﹤0.01% 1127
2023
Q1 		$328K Buy
14,456
+5,739
+66% +$140K ﹤0.01% 1071
2022
Q4 		$205K Buy
+8,717
New +$202K ﹤0.01% 1114
2022
Q1 		– Sell
-77,152
Closed -$3.31M – 1194
2021
Q4 		$3.31M Buy
77,152
+5,833
+8% +$305K ﹤0.01% 671
2021
Q3 		$4.74M Sell
71,319
-17
-0% -$1.2K 0.01% 537
2021
Q2 		$5.23M Buy
71,336
+2,474
+4% +$163K 0.01% 506
2021
Q1 		$4.71M Sell
68,862
-13,953
-17% -$1.05M 0.01% 509
2020
Q4 		$5.56M Buy
82,815
+11,138
+16% +$604K 0.01% 479
2020
Q3 		$3.69M Sell
71,677
-120
-0.2% -$5.34K 0.01% 532
2020
Q2 		$2.71M Buy
71,797
+17,898
+33% +$612K 0.01% 599
2020
Q1 		$1.61M Buy
+53,899
New +$1.63M ﹤0.01% 661

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Putnam Investments's CSTL Position: Q4 2023 in Review

Putnam Investments reduced its Castle Biosciences (CSTL) stake by 3.1% in Q4 2023, selling an estimated $13.9K and leaving 25,006 shares worth $540K. The position accounts for ﹤0.01% of the portfolio, ranked #922.

Putnam Investments first reported a position in CSTL in Q1 2020 and has held it in 13 quarters since. The position peaked at $5.56M in Q4 2020. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2023.

  • Putnam Investments held 25,006 shares of Castle Biosciences worth $540K as of Q4 2023.
  • Putnam Investments sold 789 Castle Biosciences shares in Q4 2023, an estimated $13.9K.
  • Castle Biosciences made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #922 holding.
  • Putnam Investments first reported a position in Castle Biosciences in Q1 2020 and has held it in 13 quarters since.
  • Putnam Investments's Castle Biosciences position peaked at $5.56M in Q4 2020.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.